Skip to content
ChickenStockChickenStock
ResearchCGEM
Cullinan Therapeutics logo

Cullinan Therapeutics (CGEM) stock

NASDAQ

$9.28-2.37%(-0.23)

As of the Nov 17, 2026 close (U.S. Eastern)

Events and reference metrics · 1

Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.

Price date for the multiples · Nov 17, 2026 · Financial period · Trailing twelve months

P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock

P/E

-2.97x

Net loss — not comparable

P/B

2.15x

P/S

31.74x

Find stocks with P/B ≤ 0.9×

Latest earnings

SEC filings

Jul–Sep 2026(FY2026 Q3)

Operating income increased from the same period a year earlier.

Key reported figures come first. Select one to see the same quarter across three years.

See the same quarter across three years →

Filed Nov 10, 2026 · 10-Q · SEC EDGAR

Reported results are from SEC EDGAR filings. Reference information only, not investment advice.

Insider transactions

Recent Form 4 filings grouped by person, date and transaction type.

6 SEC filings
  • Michaelson JenniferChief Scientific Officer · Nov 5, 2026Open-market sale4,000 shares · $49K
    Avg. price $12.36158,649 shares held after
  • Michaelson JenniferChief Scientific Officer · Nov 5, 2026Option exercise3,805 shares · $16K
    Avg. price $4.3162,649 shares held after
  • Michaelson JenniferChief Scientific Officer · Sep 8, 2026Open-market sale8,000 shares · $173K
    Avg. price $21.57158,844 shares held after
  • Michaelson JenniferChief Scientific Officer · Sep 8, 2026Option exercise4,000 shares · $17K
    Avg. price $4.3166,844 shares held after
  • Michaelson JenniferChief Scientific Officer · Aug 13, 2026Open-market sale30,000 shares · $608K
    Avg. price $20.26162,844 shares held after
  • Michaelson JenniferChief Scientific Officer · Aug 13, 2026Option exercise30,000 shares · $129K
    Avg. price $4.3192,844 shares held after

Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.

Recent SEC filings

40 filings

Filings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.

Company overview

Expand ▾

Cullinan Therapeutics (CGEM) stock information

NASDAQ

Cullinan Therapeutics (CGEM) is listed on NASDAQ. Its market capitalization is about $603M. On trailing-twelve-month earnings the P/E ratio is -2.97, and the P/B ratio is 2.15. Return on equity is -72.2%. These figures are computed in-house from official filings and are reference information only.

Cullinan Therapeutics — frequently asked questions

What is the P/E ratio of Cullinan Therapeutics (CGEM)?
On a trailing-twelve-month basis, CGEM trades at a P/E ratio of -2.97. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
What is the market capitalization of Cullinan Therapeutics?
CGEM has a market capitalization of about $603M. The figure moves with the share price and is refreshed each trading day.
Is this page investment advice?
No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.

All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.